Switching and stopping antidepressants
- Nicholas Keks, Judy Hope, Simone Keogh
- Aust Prescr 2016;39:76-83
- 1 June 2016
- DOI: 10.18773/austprescr.2016.039
Switching from one antidepressant to another is frequently indicated due to an inadequate treatment response or unacceptable adverse effects. All antidepressant switches must be carried out cautiously and under close observation.
Conservative switching strategies involve gradually tapering the first antidepressant followed by an adequate washout period before the new antidepressant is started. This can take a long time and include periods of no treatment with the risk of potentially life-threatening exacerbations of illness.
Clinical expertise is needed for more rapid or cross-taper switching as drug toxicity, including serotonin syndrome, may result from inappropriate co-administration of antidepressants. Some antidepressants must not be combined.
Antidepressants can cause withdrawal syndromes if discontinued abruptly after prolonged use. Relapse and exacerbation of depression can also occur. Gradual dose reduction over days to weeks reduces the risk and severity of complications.
Antidepressant drugs are indicated for the treatment of depression, anxiety disorders (including panic and social phobia), obsessive compulsive disorder and post-traumatic stress disorder. There are over 20 antidepressants currently available in Australia. These can be divided into 13 clinically relevant groups, which differ substantially in their pharmacodynamic and pharmacokinetic characteristics.
Up to two-thirds of patients with major depression fail to respond to their first antidepressant drug. After assuring correct diagnosis, optimal dose, duration and adherence to treatment, a change of antidepressant drug is indicated.1 A patient is unlikely to respond if there has been no improvement after three to four weeks on an adequate dose of antidepressant.2 About a quarter of patients switched to a second antidepressant can be expected to achieve remission.3 There is no evidence that switching between classes of antidepressants is more effective than switching within a class.4 Unacceptable adverse effects from antidepressants, such as sexual dysfunction and weight gain, may also necessitate a change of therapy.5 Switching from one antidepressant to another is a common clinical challenge.
Withdrawal of an antidepressant is also indicated after an episode of depression has been adequately treated - usually six to nine months after recovery from a single episode. Serious physical illness, pregnancy and surgery may also be reasons for stopping antidepressant therapy. Up to a third of patients stop antidepressants soon after starting and many more only partially adhere to treatment.6
If used for longer than six weeks, all antidepressants have the potential to cause withdrawal syndromes if they are stopped or rapidly reduced (with the possible exception of agomelatine). As a result many patients believe that antidepressants are addictive. This is not the case as abusive and compulsive use, tolerance and drug seeking do not occur with antidepressant drugs. Withdrawal syndromes occur with many drugs (such as corticosteroids) when used long term.
The usual recommended period for antidepressant dose reduction is a minimum of four weeks.2 However, abrupt cessation may at times be unavoidable on clinical grounds. The time frame for dose reduction also depends on individual risk for withdrawal symptoms, patient preference and experience during withdrawal, and drug characteristics such as half-life (Table 1).
|Antidepressant||Approximate half-life (days)|
|phenelzine||see below §|
|tranylcypromine||see below §|
* fluoxetine plus active metabolite norfluoxetine
† venlafaxine plus active metabolite desvenlafaxine
‡ a longer half-life (up to 65 hours) has occasionally been recorded and a shorter half-life is sometimes seen in young men
§ biological activity persists for 14–21 days
Previous withdrawal symptoms and anxiety when starting antidepressant treatment are predictors of future discontinuation problems. Some patients experience little discomfort despite abrupt cessation, while others are severely affected. In a minority, withdrawal symptoms are not diminished by extending the duration of dose taper. These patients may prefer rapid cessation and a briefer withdrawal period. Many will not experience symptoms in the early part of withdrawal (which could proceed more rapidly) but develop severe symptoms in the later stages (when dose reduction may need to be more gradual).
Withdrawal symptoms generally begin within hours to days of dose reduction, depending on the characteristics of the particular drug.7 Withdrawing selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) tends to cause flu-like symptoms, nausea, lethargy, dizziness, ataxia, ‘electric shock’ sensations, anxiety, irritability, insomnia and vivid dreams. The symptoms can be extremely disabling for some patients.
Venlafaxine is associated with the most severe withdrawal effects. Paroxetine is also troublesome while fluoxetine rarely causes withdrawal symptoms (especially if the dose is under 40 mg) due to the long half-life of the parent drug and its active metabolite (about 7 days). Withdrawal of tricyclic antidepressants can cause nausea, headache, abdominal pain, diarrhoea, lethargy, anxiety, insomnia and vivid dreams. It is unlikely that withdrawal symptoms will occur after cessation of low-dose tricyclics used in pain treatment. Withdrawing irreversible monoamine oxidase inhibitors such as tranylcypromine is particularly troublesome. It often causes agitation, irritability, mood disorders, dreams, cognitive impairment and occasionally psychosis and delirium.
Stopping antidepressants can also result in relapse or exacerbation of the psychiatric illness. Relapse of depressive symptoms (including suicidal ideation and self-harm) and recurrence of panic attacks and severe anxiety can all occur with dose reduction and cessation. Such exacerbations can cause life-threatening behaviours in high-risk patients, and antidepressant withdrawal must be a carefully considered decision made by the well-informed patient, often their family, and the prescriber. Avoid stopping an antidepressant abruptly - withdrawal over weeks to months (if possible) reduces the risk of relapse.2
A number of strategies are available for switching between antidepressants (
Table 2).6,8 Close clinical
observation and caution is required with all approaches, as some patients may
respond idiosyncratically and serious complications can occur. Individual
patient factors and illness factors may require considerable modification of a
||Most appropriate for general practice. The risk of drug interactions is very low but discontinuation symptoms may occur.|
||Also recommended for use in general practice. The risk of drug interactions is low but discontinuation symptoms may occur.|
||Quick and simple but discontinuation symptoms are likely depending on the second antidepressant. The risk of drug interactions is substantial, depending on the second antidepressant. Method requires clinical expertise and is only feasible in selected instances, such as swapping from one short half-life SSRI to another.|
||Frequently used for patients with high risk from illness relapse but there is risk of drug interactions and increased adverse effects from combined medications. Only feasible in selected instances. Requires clinical expertise.|
Note: Above strategies do not apply to monamine oxidase inhibitors, for which strict recommendations must be followed (Table 3)
SSRI selective serotonin reuptake inhibitor
Adapted from reference 6
The most conservative strategy, with the lowest risk of drug interactions, is to gradually taper the dose of the first antidepressant to minimise withdrawal symptoms then start a washout period equivalent to five half-lives of the drug (Table 1). This does not apply to irreversible monoamine oxidase inhibitors where a specified long period of washout is mandatory (see Table 3). Five half-lives equates to about five days for most SSRIs except fluoxetine, which can still be significantly active five or more weeks after cessation. The second antidepressant is then introduced according to the starting dose recommendations.
The dose is usually tapered over four weeks, similar to the minimum period required for antidepressant discontinuation. However, the time frame may need to be modified depending on patient factors.
As the conservative switch can take quite a long time and usually includes at least several days where the patient is not on an antidepressant, a compromise strategy is the moderate switch. Here the washout period can generally be shortened to about two days. The risk of drug interactions is increased with this approach, but is still quite low. The conservative and moderate switch techniques are both suitable for general practice.
Direct and cross-taper switch methods can also be used but considerable expertise is necessary (Table 2). Some patients will require admission to hospital. A direct switch – one drug is stopped and another drug is commenced the next day at the usual therapeutic dose – can be used when switching between some SSRIs, SNRIs and tricyclic antidepressants. However, there will be a considerable risk of withdrawal symptoms and drug interactions. A cross-taper strategy, where the first antidepressant dose is reduced while the second antidepressant is introduced at a low dose and gradually increased, can be done safely with only some antidepressants (Table 3).
Table 3 lists generalised guidelines for switching patients from one antidepressant to another.2,8-10 The recommendations are applicable to any switching strategy. Circumstances where only a conservative strategy can be used are identified. Table 3 also states when antidepressants should not be co-administered or tapered at the same time.
As many antidepressants have serotonergic activity, serotonin syndrome can occur during antidepressant switching. While the syndrome may cause mild symptoms such as nervousness, agitation, tremor, diaphoresis, shivering, mydriasis, hyperreflexia and diarrhoea, in more severe cases tachycardia, hyperthermia, hypertension, myoclonus, muscular rigidity and delirium can occur. Convulsions, organ system failure and death may follow. Prevention through minimising interactions between potent serotonergic drugs is critical.11
The only significant interaction for agomelatine is with fluvoxamine (Table 3). Vortioxetine (an SSRI with possible other serotonergic effects) can interact with a variety of antidepressants. Caution is required for switching and the prescriber should consult relevant drug information before proceeding. The same caution applies to duloxetine (Table 3).
Fluoxetine is a particular challenge for switching because of its long half-life. Serotonin syndrome can occur if clomipramine, fluvoxamine or monoamine oxidase inhibitors are introduced before an adequate washout of fluoxetine, which can take five or more weeks. Tricyclic antidepressants can be introduced at a low dose after fluoxetine withdrawal. However, the low dose needs to be continued for several weeks to avoid cardiotoxic plasma concentrations of tricyclic antidepressant due to inhibition of tricyclic antidepressant metabolism by fluoxetine. Early signs of tricyclic antidepressant toxicity include drowsiness, tachycardia and postural hypotension.
When changing from irreversible monoamine oxidase inhibitors (phenelzine and tranylcypromine) to all other antidepressants, with the possible exception of agomelatine, an adequate washout of two to three weeks is mandatory.
Switching antidepressants involves drug cessation, which may cause withdrawal symptoms and relapse or exacerbation of the psychiatric illness. Gradual antidepressant withdrawal reduces the risk of complications. If the washout period is not long enough (defined by half-life of the drug), introducing a new antidepressant can cause drug interactions leading to toxicity, particularly serotonin syndrome. Switching from one antidepressant to another requires careful observation and caution.
Conflict of interest: none declared
Director, Centre for Mental Health Education and Research, Delmont Private Hospital
Adjunct professor, Monash University, Melbourne
Deputy director, Centre for Mental Health Education and Research, Delmont Private Hospital
Senior lecturer, Monash University, Melbourne
Psychiatrist and senior fellow, Centre for Mental Health Education and Research, Delmont Private Hospital